Drugs and trafficking of ion channels: a new pro‐arrhythmic threat on the horizon?
- 1 February 2008
- journal article
- editorial
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (3), 406-409
- https://doi.org/10.1038/sj.bjp.0707618
Abstract
Tuning of functional expression levels of the ion channels that make up the cardiac action potential (AP) is crucial for preserving correct AP duration (APD) and QTc times. Many compounds inhibit human ether-à-go-go related gene (hERG)-mediated delayed rectifier currents and thus prolong cardiac repolarization that may cause life-threatening arrhythmias like Torsades de Pointes. An increasing number of drugs are found to inhibit hERG function by a dual mechanism of short-term channel block and long-term trafficking defects that operate over different time and concentration scales. In safety screens at present used by pharmaceutical companies, the short-term effect of channel block is covered. In contrast, specific screening for long-term trafficking defects is not common, with the consequent risk of drugs that disturb trafficking entering the market. Whether that poses another pro-arrhythmic threat for the patients treated has to be determined, but is not unlikely.Keywords
This publication has 28 references indexed in Scilit:
- Coexistence of hERG current block and disruption of protein trafficking in ketoconazole‐induced long QT syndromeBritish Journal of Pharmacology, 2008
- Co-chaperone FKBP38 Promotes HERG TraffickingJournal of Biological Chemistry, 2007
- Mechanisms of cardiac potassium channel traffickingThe Journal of Physiology, 2007
- Drug block of the hERG potassium channel: Insight from modelingProteins-Structure Function and Bioinformatics, 2007
- Identification of IKr and Its Trafficking Disruption Induced by Probucol in Cultured Neonatal Rat CardiomyocytesThe Journal of pharmacology and experimental therapeutics, 2007
- Cardiac Glycosides as Novel Inhibitors of Human Ether-a-go-go-Related Gene Channel TraffickingThe Journal of pharmacology and experimental therapeutics, 2006
- Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetineBritish Journal of Pharmacology, 2006
- Combined hERG channel inhibition and disruption of trafficking in drug‐induced long QT syndrome by fluoxetine: a case‐study in cardiac safety pharmacologyBritish Journal of Pharmacology, 2006
- Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmiasPharmacology & Therapeutics, 2006
- Inhibition of the HERG K+channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656FEBS Letters, 2006